A Phase 3, Prospective, Double Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis
Latest Information Update: 23 May 2022
At a glance
- Drugs DHACM (Primary)
- Indications Musculoskeletal pain; Pain
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors MiMedx
- 18 May 2022 Status changed from active, no longer recruiting to completed.
- 28 Apr 2021 According to a MiMedx media release, top-line results expected later this summer.
- 19 Apr 2021 According to a MiMedx media release, The Company does not anticipate pursuing a BLA for Achilles Tendonitis at this time, and plans to review options for this program after assessing the results of the Phase 3 study, including potentially exploring the efficacy of AmnioFix Injectable in a more well-defined subset of patients.